Robin Jolliffe joined Pear Therapeutics in 2018 as Vice President, Marketing. Prior to Pear, Ms. Jolliffe was at Bioverativ (NASDAQ: BIVV, prior to Sanofi acquisition) where she played a large role establishing the organization as a newly formed rare hematology company (a spin-off of Biogen, Inc.) through her role as Vice President of Marketing for the hemophilia products ELOCTATE® and ALPROLIX® as well as pipeline products. Previously, Ms. Jolliffe held several roles at Biogen (NASDAQ: BIIB) including Head of Global Marketing for Hemophilia, Global Business Lead of an enterprise-wide technology program of business enabling software and business processes, and Director of Global Marketing of AVONEX®.
Ms. Jolliffe held other key commercial leadership roles at multiple companies including AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) and Genzyme (acquired by Sanofi). Ms. Jolliffe started her career at Eli Lilly & Co. with a focus on marketing, new products planning and sales.
Ms. Jolliffe earned her B.A. in Journalism with a concentration of Advertising from the University of Maine and her M.B.A, in Marketing from The Maine Business School also at the University of Maine. Ms. Jolliffe is based in the Boston, MA office.